XBiotech Announces Positive Phase II Final Efficacy Results from Investigator-Sponsored TASKIN Trial in Refractory Metastatic Colorectal Cancer

Go back to XBiotech Announces Positive Phase II Final Efficacy Results from Investigator-Sponsored TASKIN Trial in Refractory Metastatic Colorectal Cancer
(NASDAQ: XBIT) Delayed: 1.93 -0.04 (2.03%)
Previous Close $1.97    52 Week High $25.00 
Open $1.95    52 Week Low $6.36 
Day High $1.95    P/E N/A 
Day Low $1.86    EPS $0.00 
Volume 121,737